MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
+0.210
+9.91%
Opening 10:38 11/24 EST
OPEN
2.100
PREV CLOSE
2.120
HIGH
2.370
LOW
2.030
VOLUME
834.03K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
0.5500
MARKET CAP
40.14M
P/E (TTM)
-1.3763
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Precipio, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Precipio, Inc.
ACCESSWIRE · 4d ago
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
Precipio Announces Q3-2020 Shareholder Update Call
Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2020 corporate update call on Thursday, November 19th at 5:00 PM ET. The call will include updates on the company’s current core businesses, as well as an update on the company’s COVID-19 testing initiative. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10150005/dd310278c1 and will receive a calendar invite and a direct dial-in number, bypassing the operator.Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call.A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, http://www.precipiodx.com/investors.html.About PrecipioPrecipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings. The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.   CONTACT: Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
GlobeNewswire · 11/11 14:00
Healthcare rallies as Presidential vote count continues
The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep
Seekingalpha · 11/04 17:12
SNBR, GRFS among premarket gainers
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products
Seekingalpha · 10/15 12:24
Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™
Prominent Laboratories in US and Europe will begin testing the mediaNEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with its partner ADS Biotec announce the launch of the beta phase testing for its new IV-cell cytogenetics
GlobeNewswire · 10/06 14:00
BIG, FIT among premarket gainers
U.S. Energy (USEG) +168% after entering producing assets purchase agreement.Houston American Energy (HUSA) +77%.PEDEVCO (PED) +56%.Greenpro Capital Corp. (GRNQ) +53%.Flux Power Holdings (FLUX) +36% on FY results.Mexco Energy (MXC) +33%.Westwater Resources (WWR) +30%.New Concept
Seekingalpha · 09/29 12:23
Precipio launches leukemia diagnostic panel
Precipio ([[PRPO]] +5.9%) has launched its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering.Laboratories can test that patient sample
Seekingalpha · 09/22 16:07
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRPO stock price target is 4.150 with a high estimate of 6.30 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 632.58K
% Owned: 3.67%
Shares Outstanding: 17.23M
TypeInstitutionsShares
Increased
3
226.63K
New
8
207.87K
Decreased
2
15.09K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.21%
Healthcare Equipment & Supplies
+0.21%
Key Executives
Chairman/Director
Douglas Fisher
President/Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Vice President/Director of Sales
Douglas Sites
Other
Ori Karev
Director
David Cohen
Director
Mark Rimer
Director
Richard Sandberg
Independent Director
Jeffrey Cossman
Independent Director
Kathleen LaPorte
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRPO
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.